CN114478722B - 一种细菌素Bacin A1及其应用 - Google Patents
一种细菌素Bacin A1及其应用 Download PDFInfo
- Publication number
- CN114478722B CN114478722B CN202210121331.5A CN202210121331A CN114478722B CN 114478722 B CN114478722 B CN 114478722B CN 202210121331 A CN202210121331 A CN 202210121331A CN 114478722 B CN114478722 B CN 114478722B
- Authority
- CN
- China
- Prior art keywords
- bacteriocin
- staphylococcus aureus
- application
- polypeptide
- synthesis method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010062877 Bacteriocins Proteins 0.000 title claims abstract description 42
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 239000000022 bacteriostatic agent Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 8
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 8
- 108090000623 proteins and genes Proteins 0.000 abstract description 6
- 241000894006 Bacteria Species 0.000 abstract description 5
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 3
- 229940124350 antibacterial drug Drugs 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 239000007791 liquid phase Substances 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 abstract description 2
- 238000001308 synthesis method Methods 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 239000003139 biocide Substances 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 230000002949 hemolytic effect Effects 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 206010041925 Staphylococcal infections Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- DRDWXKWUSIKKOB-PJODQICGSA-N Arg-Trp-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(O)=O DRDWXKWUSIKKOB-PJODQICGSA-N 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- DJCAHYVLMSRBFR-QXEWZRGKSA-N Asp-Met-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O DJCAHYVLMSRBFR-QXEWZRGKSA-N 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241001217102 Bacillus sp. X Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DBJYVKDPGIFXFO-BQBZGAKWSA-N Gly-Met-Ala Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O DBJYVKDPGIFXFO-BQBZGAKWSA-N 0.000 description 1
- REJKOQYVFDEZHA-SLBDDTMCSA-N Ile-Asp-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N REJKOQYVFDEZHA-SLBDDTMCSA-N 0.000 description 1
- SVBAHOMTJRFSIC-SXTJYALSSA-N Ile-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SVBAHOMTJRFSIC-SXTJYALSSA-N 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- FLCMXEFCTLXBTL-DCAQKATOSA-N Lys-Asp-Arg Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N FLCMXEFCTLXBTL-DCAQKATOSA-N 0.000 description 1
- KYNNSEJZFVCDIV-ZPFDUUQYSA-N Lys-Ile-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O KYNNSEJZFVCDIV-ZPFDUUQYSA-N 0.000 description 1
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- BDWDMRSGCXEDMR-WFBYXXMGSA-N Trp-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N BDWDMRSGCXEDMR-WFBYXXMGSA-N 0.000 description 1
- GQHAIUPYZPTADF-FDARSICLSA-N Trp-Ile-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 GQHAIUPYZPTADF-FDARSICLSA-N 0.000 description 1
- UMPVMAYCLYMYGA-ONGXEEELSA-N Val-Leu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O UMPVMAYCLYMYGA-ONGXEEELSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 108010078114 alanyl-tryptophyl-alanine Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000941 anti-staphylcoccal effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3526—Organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明属于医药应用领域，具体涉及一种细菌素Bacin A1及其应用。所述细菌素Bacin A1具有如SEQ ID NO.1所示的氨基酸序列，可以采用多肽固相合成法或液相多肽合成法合成，也可以将所述细菌素Bacin A1的编码基因在工程菌中表达得到。其结构简单，安全低毒，合成较容易，能高效杀灭金黄色葡萄球菌，可用于抗菌药物、饲料、食品等领域，具有广阔的应用前景。
Description
技术领域
本发明属于医药应用领域，具体涉及一种细菌素Bacin A1及其应用。
背景技术
金黄色葡萄球菌是全球院内感染的首要病原菌，可引起皮肤和软组织感染、菌血症、骨髓炎、脓毒性关节炎、肺炎、心内膜炎等疾病。临床分离的80％以上金葡菌对为耐甲氧西林金葡菌(MRSA)，因其多重耐药性，抗MRSA感染日益成为抗感染治疗的热点和难点，因此迫切需要新的抗MRSA药物。细菌素是由细菌通过核糖体合成机制产生的一类具有抗菌活性的蛋白质或多肽类物质。目前，一些芽胞杆菌产生的细菌素，如在蜡样芽胞杆菌As1.1846中报道的羊毛硫细菌素cerecin对耐甲氧西林金葡菌(MRSA)具有显著的抑菌活性。研究表明芽胞杆菌中依然存在大量未鉴定的新颖细菌素，这些新颖细菌素可被鉴定、开发做新型抗MRSA药物，具有重要开发应用前景。
发明内容
本发明的第一个目的，提供一种细菌素Bacin A1，具有如SEQ ID NO.1所示的氨基酸序列。本发明的细菌素Bacin A1可以采用多肽固相合成法或液相多肽合成法合成，也可以将所述细菌素Bacin A1的编码基因在工程菌中表达得到。
本发明的第二个目的，提供所述的细菌素Bacin A1在制备抑菌剂中的应用，该抑制剂抑制金黄色葡萄球菌。
本发明的第三个目的，提供所述的细菌素Bacin A1在制备用于治疗金黄色葡萄球菌染性疾病的药物中的应用。
本发明的第四个目的，提供一种用于治疗金黄色葡萄球菌染性疾病的药物，包含所述细菌素Bacin A1、一种或多种药学上可接受的载体、赋形剂和/或稀释剂。
本发明的第五个目的，提供一种用于抑制金黄色葡萄球菌的抑菌剂，其包含所述细菌素Bacin A1。
本发明的第六个目的，提供一种含有所述抑菌剂的饲料。
本发明的第七个目的，提供含有所述抑菌剂的食品。
本发明具有如下有益效果：
本发明所述的细菌素Bacin A1结构简单，安全低毒，合成较容易，能高效杀灭金黄色葡萄球菌。本发明的细菌素Bacin A1可用于抗菌药物、饲料、食品等领域，具有广阔的应用前景。
附图说明
图1为实施例3中细菌素Bacin A1的溶血活性图。
具体实施方式
下面结合附图和具体实施例对本发明进行详细说明，但不应理解为本发明的限制。如未特殊说明，下述实施例中所用的技术手段为本领域技术人员所熟知的常规手段，下述实施例中所用的材料、试剂等，如无特殊说明，均可从商业途径得到。
实施例1：细菌素Bacin A1的获得
本发明提出的细菌素来源于我们构建的芽胞杆菌XIN-TL12(Bacillus sp.X IN-TL2，该菌的保藏编号为CCTCC NO：M 2021718)的多肽序列数据库，其氨基酸序列(SEQ IDNO.1所示)如下：MITFLRIVAQLGVRAARWAWANK DRVLGWIRDGMAIDWIINKINDMVN，如序列表SEQID NO.1所示。通过在线BlastP比对分析(Protein BLAST:search protein databasesusing a protein query(nih.gov))，该细菌素与已鉴定、报道的细菌素的氨基酸序列均无同源性，说明它是一种新颖细菌素，属发明人首次研究、鉴定、报道。根据所示的氨基酸序列，经吉尔生化(上海)有限公司合成得到对应的抗菌多肽，其纯度>95％。
实施例2：细菌素Bacin A1抗金黄色葡萄球菌活性的测定
以生理盐水为稀释液，通过二倍稀释法配置系列梯度的细菌素溶液(0.5，1，2，4，8μM)。利用琼脂扩散法检测不同浓度下的Bacin A1对金黄色葡萄球菌的最低抑菌浓度(MIC)。在未凝固的琼脂培养基中加入适量的指示菌(细菌个数约为5×105cfu/mL)，混匀，倒平板。选取金黄色葡萄球菌ATCC 6538、金黄色葡萄球菌ATCC 43300、金黄色葡萄球菌ATCC 12600为指示菌。待其凝固后用孔径为6mm的打孔器打孔。每孔中加入约50μL样品后将平板先放置于4℃，2h左右，让待测样品充分扩散，而后放置于30℃下培养12h，观察抑菌效果(观察有无透明的抑菌圈出现)。经测定Bacin A1对金黄色葡萄球菌ATCC 6538、金黄色葡萄球菌ATCC 43300、金黄色葡萄球菌ATCC 12600的最小抑菌浓度分别为0.5μM，1μM，1μM(表1)。
表1细菌素Bacin A1对金黄色葡萄球菌最小抑菌浓度
实施例3：细菌素Bacin A1溶血活性的测定
采集健康人新鲜血液3mL(添加抗凝血剂)，3000g离心5min，弃血浆收集红细胞。将收集的红细胞用生理盐水洗涤三遍，并按2％(V/V)的比例重悬血细胞。在无菌的96孔细胞培养板中加入100μL红细胞重悬液，再分别加入不同浓度的细菌素溶液，每个细菌素浓度设置3个平行。以0.1％Tritonx-100作为完全溶血的阳性对照，以生理盐组作为不溶血的阴性对照。37℃孵育2h，3000g离心10min。将离心后的上清转移到新的无菌96孔细胞培养板中，并利用酶标仪检测570nm处的光吸收值，计算细菌素的溶血活性。
细菌素BacinA1的溶血活性如图1所示，该细菌素在100μM的浓度下仅表现出1.6％的溶血活性，说明其毒副作用非常低。
尽管已描述了本发明的优选实施例，但本领域内的技术人员一旦得知了基本创造性概念，则可对这些实施例作出另外的变更和修改。所以，所附权利要求意欲解释为包括优选实施例以及落入本发明范围的所有变更和修改。
显然，本领域的技术人员可以对本发明进行各种改动和变型而不脱离本发明的精神和范围。这样，倘若本发明的这些修改和变型属于本发明权利要求及其等同技术的范围之内，则本发明也意图包含这些改动和变型在内。
序列表
<110> 淮北师范大学
<120> 一种细菌素Bacin A1及其应用
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 48
<212> PRT
<213> 人工序列
<400> 1
Met Ile Thr Phe Leu Arg Ile Val Ala Gln Leu Gly Val Arg Ala Ala
1 5 10 15
Arg Trp Ala Trp Ala Asn Lys Asp Arg Val Leu Gly Trp Ile Arg Asp
20 25 30
Gly Met Ala Ile Asp Trp Ile Ile Asn Lys Ile Asn Asp Met Val Asn
35 40 45
Claims (5)
1.一种细菌素Bacin A1，其特征在于，所述细菌素Bacin A1的氨基酸序列如SEQ IDNO.1所示。
2.权利要求1所述的细菌素Bacin A1在制备抑菌剂中的应用，其特征在于，该抑菌剂抑制金黄色葡萄球菌。
3.权利要求1所述的细菌素Bacin A1在制备用于治疗金黄色葡萄球菌感染性疾病的药物中的应用。
4.一种用于治疗金黄色葡萄球菌感染性疾病的药物，其特征在于，包含权利要求1所述细菌素Bacin A1以及一种或多种药学上可接受的载体、赋形剂和/或稀释剂。
5.一种用于抑制金黄色葡萄球菌的抑菌剂，其特征在于，包含权利要求1所述细菌素Bacin A1。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210121331.5A CN114478722B (zh) | 2022-02-09 | 2022-02-09 | 一种细菌素Bacin A1及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210121331.5A CN114478722B (zh) | 2022-02-09 | 2022-02-09 | 一种细菌素Bacin A1及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114478722A CN114478722A (zh) | 2022-05-13 |
| CN114478722B true CN114478722B (zh) | 2023-07-21 |
Family
ID=81478409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210121331.5A Active CN114478722B (zh) | 2022-02-09 | 2022-02-09 | 一种细菌素Bacin A1及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114478722B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116041453B (zh) * | 2022-09-16 | 2024-01-26 | 河南牧业经济学院 | 一种抗多种食源性病原菌的无前导肽细菌素subticin A1及应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101643501A (zh) * | 2008-11-07 | 2010-02-10 | 畿晋庆三联（北京）生物技术有限公司 | 一种新型抗生素及其核苷酸序列、制备方法与应用 |
| CN103214583A (zh) * | 2013-04-15 | 2013-07-24 | 中国农业大学 | 细菌素lacticin Q的分泌表达方法 |
| WO2019046577A1 (en) * | 2017-08-31 | 2019-03-07 | Syngulon Sa | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF BACTERIOCIN AND ANTIMICROBIAL PEPTIDES |
| CN111757890A (zh) * | 2017-12-19 | 2020-10-09 | 辛格隆股份公司 | 发酵工艺 |
| CN112513251A (zh) * | 2018-06-06 | 2021-03-16 | 辛格隆股份公司 | 改造的抗微生物肽 |
-
2022
- 2022-02-09 CN CN202210121331.5A patent/CN114478722B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101643501A (zh) * | 2008-11-07 | 2010-02-10 | 畿晋庆三联（北京）生物技术有限公司 | 一种新型抗生素及其核苷酸序列、制备方法与应用 |
| CN103214583A (zh) * | 2013-04-15 | 2013-07-24 | 中国农业大学 | 细菌素lacticin Q的分泌表达方法 |
| WO2019046577A1 (en) * | 2017-08-31 | 2019-03-07 | Syngulon Sa | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF BACTERIOCIN AND ANTIMICROBIAL PEPTIDES |
| CN111757890A (zh) * | 2017-12-19 | 2020-10-09 | 辛格隆股份公司 | 发酵工艺 |
| CN112513251A (zh) * | 2018-06-06 | 2021-03-16 | 辛格隆股份公司 | 改造的抗微生物肽 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114478722A (zh) | 2022-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mishra et al. | Antibacterial, antifungal, anticancer activities and structural bioinformatics analysis of six naturally occurring temporins | |
| Cao et al. | StCT2, a new antibacterial peptide characterized from the venom of the scorpion Scorpiops tibetanus | |
| CN113307855A (zh) | 拟穴青蟹抗菌多肽Spampcin56-86及其应用 | |
| CN108276485A (zh) | 能抑制和杀灭革兰氏阴性菌的抗菌肽hv2及制备方法 | |
| CN104592360A (zh) | 碱性抗菌肽及其靶向设计和应用 | |
| CN114478722B (zh) | 一种细菌素Bacin A1及其应用 | |
| CN114437187B (zh) | 一种细菌素Bacin A4及其应用 | |
| CN110498848B (zh) | 一种蜂毒肽变体及其应用 | |
| CN104650208B (zh) | 一种鸡源抗菌肽的衍生肽及其制备方法和应用 | |
| CN115536737A (zh) | 眼镜王蛇抗菌肽oh-cath30在抗水产动物致病菌中的应用 | |
| CN114409750B (zh) | 一种细菌素Bacin A3及其应用 | |
| CN107141338B (zh) | 一种抗菌肽rw-p及其制作方法和应用 | |
| CN110305193B (zh) | 一种抗牙龈卟啉单胞菌多肽及应用 | |
| CN103288924B (zh) | 鲶鱼抗菌肽突变体及其制备方法 | |
| Tamaki et al. | Polycationic gramicidin S analogues with both high antibiotic activity and very low hemolytic activity | |
| CN115850409B (zh) | 一种抗多种病原菌的无前导肽细菌素subticin A3及制备方法与应用 | |
| CN113603748B (zh) | 一种β-折叠抗菌肽HINGE-RV及其制备方法和应用 | |
| CN110551191B (zh) | 一种低溶血活性的蜂毒肽及其应用 | |
| CN114702554A (zh) | 抗菌肽nzx在制备无乳链球菌抗菌药物中的应用 | |
| CN112724198A (zh) | 一种抗耐甲氧西林金黄色葡萄球菌抗菌肽及其制备方法和应用 | |
| CN111378023B (zh) | 一种抗变异链球菌多肽及其应用 | |
| CN117069819B (zh) | 一种黑腹狼蛛抗菌肽lc-amp-i1及其应用 | |
| CN109748949B (zh) | 一种抗菌肽及其应用 | |
| CN115109130A (zh) | 一种细菌素Thurisin A2及其应用 | |
| CN109867710A (zh) | 一种新型广谱抗菌肽samp1-a3及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |